Publications by authors named "Camil Fuchs"

Claim this Profile
R
Rate of OCD and sub-threshold OCD in bipolar disorder patients with first depressive episode.
Leonid Braverman, Camil Fuchs, Abraham Weizman, Michael Poyurovsky

Psychiatry Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD247, a novel T cell-derived diagnostic and prognostic biomarker for detecting disease progression and severity in patients with type 2 diabetes.
Roy Eldor, Yair Klieger, Moshe Sade-Feldman, Ilan Vaknin, Inna Varfolomeev, Camil Fuchs

Diabetes Care· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
Avi Amrami-Weizman, Rachel Maayan, Irit Gil-Ad, Artashez Pashinian, Camil Fuchs

Psychopharmacology (Berl)· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Michael Poyurovsky, Camil Fuchs, Artashez Pashinian, Adva Levi, Ronit Weizman

Psychopharmacology (Berl)· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age matters:  Young T lymphocytes offer better protection from myeloma proliferation.
Alexander F Glick, Yan S Song, Brian Hwang, John Lillvis, Pat Zanzonico, Camil Fuchs

Immun Ageing· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder.
Sarit Faragian, Camil Fuchs, Artashes Pashinian, Ronit Weizman, Abraham Weizman

Psychiatry Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Michael Poyurovsky, Sarit Faragian, Camil Fuchs, Artashez Pashinian

Isr J Psychiatry Relat Sci· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder.
Sarit Faragian, Artashes Pashinian, Camil Fuchs, Michael Poyurovsky

Prog Neuropsychopharmacol Biol Psychiatry· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of schizotypal-related obsessive-compulsive disorder.
Michael Poyurovsky, Sarit Faragian, Artashez Pashinian, Lilah Heidrach, Camil Fuchs

Psychiatry Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder.
Michael Poyurovsky, Sarit Faragian, Vered Kleinman-Balush, Artashez Pashinian, Rena Kurs, Camil Fuchs

J Nerv Ment Dis· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Michael Poyurovsky, Camil Fuchs, Artashez Pashinian, Aya Levi, Sarit Faragian

Psychopharmacology (Berl)· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder.
Michael Poyurovsky, Sarit Faragian, Artashes Pashinian, Aya Levi, Alexander Viosburd, Camil Fuchs

J Neuropsychiatry Clin Neurosci· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute otitis media and mastoid growth.
Jacob Sadé, Eyal Russo, Camil Fuchs, Amos Ar

Acta Otolaryngol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder.
Michael Poyurovsky, Camil Fuchs, Sarit Faragian, Victoria Kriss, Gregory Weisman

Can J Psychiatry· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obsessive-compulsive disorder in bipolar disorder patients with first manic episode.
Artashez Pashinian, Sarit Faragian, Aya Levi, Maruke Yeghiyan, Khachatur Gasparyan, Camil Fuchs

J Affect Disord· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.
Michael Poyurovsky, Artashes Pashinian, Ronit Weizman, Camil Fuchs, Abraham Weizman

Biol Psychiatry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD.
Michael Poyurovsky, Victoria Kriss, Gregory Weisman, Sarit Faragian, Michael Schneidman, Camil Fuchs

Am J Med Genet B Neuropsychiatr Genet· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Michael Poyurovsky, Vered Tal, Rachel Maayan, Irit Gil-Ad, Camil Fuchs

Eur Neuropsychopharmacol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia.
Michael Poyurovsky, Victoria Kriss, Gregory Weisman, Sarit Faragian, Rena Kurs, Camil Fuchs

J Clin Psychiatry· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study.
Michael Poyurovsky, Svetlana Epshtein, Camil Fuchs, Michael Schneidman, Ronit Weizman

J Clin Psychopharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obsessive-compulsive disorder in adolescent schizophrenia patients.
Allon Nechmad, Gideon Ratzoni, Michael Poyurovsky, Sorin Meged, Gideon Avidan, Camil Fuchs

Am J Psychiatry· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is secretory otitis media a single disease entity?
Jacob Sadé, Eyal Russo, Camil Fuchs, David Cohen

Ann Otol Rhinol Laryngol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study.
Michael Poyurovsky, Danny Koren, Inna Gonopolsky, Michael Schneidman, Camil Fuchs

Eur Neuropsychopharmacol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barotrauma vis-a-vis the "chronic otitis media syndrome": two conditions with middle ear gas deficiency Is secretory otitis media a contraindication to air travel?
Jacob Sadé, Amos Ar, Camil Fuchs

Ann Otol Rhinol Laryngol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Michael Poyurovsky, Ilanit Isaacs, Camil Fuchs, Michael Schneidman, Sarit Faragian

Am J Psychiatry· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis